Literature DB >> 14758155

Hypothalamic-pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 levels.

Ioanna Dimopoulou1, Stylianos Tsagarakis, Andreas T Kouyialis, Paraskevi Roussou, Georgios Assithianakis, Marietta Christoforaki, Ioannis Ilias, Damianos E Sakas, Nikolaos Thalassinos, Charis Roussos.   

Abstract

OBJECTIVE: To investigate hypothalamic-pituitary-adrenal axis function in patients requiring mechanical ventilation for traumatic brain injury and to assess the relation of hypothalamic-pituitary-adrenal axis abnormalities with vasopressor dependence and peripheral cytokine levels.
DESIGN: Prospective study.
SETTING: General intensive care unit in a university teaching hospital. PATIENTS: Forty patients (33 men and 7 women) with moderate to severe traumatic brain injury (mean age, 37 +/- 16 yrs) were studied the day after termination of mechanical ventilation (7-60 days after trauma).
INTERVENTIONS: First, a morning blood sample was obtained to measure baseline cortisol, corticotropin, interleukin-6, and tumor necrosis factor alpha. Subsequently, 1 microg of synthetic corticotropin was injected intravenously, and 30 mins later, a second blood sample was drawn to determine stimulated plasma cortisol. Based on data derived from healthy volunteers, patients having stimulated cortisol levels <18 microg/dL were defined as nonresponders to the low-dose stimulation test. Thirty-one patients underwent also a human corticotropin releasing hormone test.
MEASUREMENTS AND MAIN RESULTS: In traumatic brain injury patients, mean baseline and low-dose stimulation test-stimulated cortisol levels were 17.2 +/- 5.4 microg/dL and 24.0 +/- 6.6 microg/dL, respectively. The median increment in cortisol was 5.9 microg/dL. Basal corticotropin levels ranged from 3.9 to 118.5 pg/mL. Six of the 40 patients (15%) failed the low-dose stimulation test. The human corticotropin releasing hormone test (performed in 26 responders and five nonresponders) revealed diminished cortisol release only in the low-dose stimulation test nonresponder patients. Corticotropin responses to corticotropin releasing hormone were consistent with both primary (three patients) and/or secondary (two patients) adrenal dysfunction. In retrospect, nonresponders to the low-dose stimulation test more frequently required vasopressors (6/6 [100%] vs. 16/34 [47%]; p =.02) and for a longer time interval (median, 0 vs. 293 hrs; p =.006) compared with responders. Furthermore, nonresponders had higher interleukin-6 levels compared with responders (56.03 vs. 28.04 pg/mL; p =.01), whereas tumor necrosis factor alpha concentrations were similar in the two groups (2.42 vs. 1.55 pg/mL; p =.53).
CONCLUSIONS: Adrenal cortisol secretion after dynamic stimulation is deficient in a subset of critically ill patients with moderate to severe head injury. This disorder is associated with prior vasopressor dependency and higher interleukin-6 levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14758155     DOI: 10.1097/01.CCM.0000108885.37811.CA

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  32 in total

1.  Serum cytokines and critical illness-related corticosteroid insufficiency.

Authors:  Yong Soo Kwon; Gee Young Suh; Kyeongman Jeon; So Young Park; So Yeon Lim; Won-Jung Koh; Man Pyo Chung; Hojoong Kim; O Jung Kwon
Journal:  Intensive Care Med       Date:  2010-07-28       Impact factor: 17.440

2.  Correlation between brain interstitial and total serum cortisol levels in traumatic brain injury. A preliminary study.

Authors:  J A Llompart-Pou; G Pérez; J Pérez-Bárcena; M Brell; J Ibáñez; M Riesco; J M Abadal; J Homar; P Marsé; J Ibáñez; B Burguera; J M Raurich
Journal:  J Endocrinol Invest       Date:  2010-06       Impact factor: 4.256

Review 3.  Brain-lung crosstalk: Implications for neurocritical care patients.

Authors:  Ségolène Mrozek; Jean-Michel Constantin; Thomas Geeraerts
Journal:  World J Crit Care Med       Date:  2015-08-04

4.  Adrenal insufficiency after brain injury.

Authors:  Francis Bernard; Basil F Matta
Journal:  Intensive Care Med       Date:  2006-03-29       Impact factor: 17.440

5.  Comment on "the Lund Concept for the treatment of severe head trauma-physiological principles and clinical application".

Authors:  Juan A Llompart-Pou; Jon Pérez-Bárcena; Josep M Abadal; Javier Homar
Journal:  Intensive Care Med       Date:  2006-10-13       Impact factor: 17.440

6.  Endocrine alterations in critically ill patients with stroke during the early recovery period.

Authors:  Ioanna Dimopoulou; Andreas T Kouyialis; Stylianos Orfanos; Apostolos Armaganidis; Marinella Tzanela; Nikolaos Thalassinos; Stylianos Tsagarakis
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

7.  Adrenal-exhaustion syndrome in patients with liver disease.

Authors:  Paul E Marik
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

8.  Prognostic value of relative adrenal insufficiency after out-of-hospital cardiac arrest.

Authors:  Frédéric Pene; Hervé Hyvernat; Vincent Mallet; Alain Cariou; Pierre Carli; Christian Spaulding; Marie-Annick Dugue; Jean-Paul Mira
Journal:  Intensive Care Med       Date:  2005-04-19       Impact factor: 17.440

9.  The low-dose corticotropin stimulation test in acute traumatic and non-traumatic brain injury: incidence of hypo-responsiveness and relationship to outcome.

Authors:  Ioanna Dimopoulou; Stylianos Tsagarakis; Evangelia Douka; Maria Zervou; Andreas T Kouyialis; Urania Dafni; Nikolaos Thalassinos; Charis Roussos
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

10.  A prospective study on the incidence and predictive factors of relative adrenal insufficiency in Korean critically-ill patients.

Authors:  Yong Soo Kwon; Eunhae Kang; Gee Young Suh; Won-Jung Koh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Jae Hoon Chung
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.